Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 2/20 | 0.66 |
| ▸ | SCN4A | P35499 | 2/20 | 0.66 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.66 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.66 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.66 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.66 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.66 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GLA | P06280 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PEX14 | O75381 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13583699 | 0.95 | SCN1A (0.64) | SCN1ASCN4ASCN5ASCN9ASCN2A | |
| SCHEMBL1768481 | 0.88 | SCN1A (0.71) | SCN1ASCN4ASCN5ASCN9ASCN2A | |
| SCHEMBL13640223 | 0.87 | SCN1A (0.58) | SCN1ASCN4ASCN5ASCN9ASCN2A | |
| SCHEMBL1768419 | 0.87 | SCN1A (0.58) | SCN1ASCN4ASCN5ASCN9ASCN2A | |
| SCHEMBL12648966 | 0.87 | SCN8A (0.76) | SCN1ASCN4ASCN5ASCN9ASCN2A | |
| SCHEMBL1768309 | 0.86 | SCN8A (0.67) | SCN1ASCN4ASCN5ASCN9ASCN2A | |
| SCHEMBL1768453 | 0.86 | SCN1A (0.56) | SCN1ASCN4ASCN5ASCN9ASCN2A | |
| SCHEMBL13582897 | 0.86 | SCN1A (0.82) | SCN1ASCN4ASCN5ASCN9ASCN2A | |
| SCHEMBL11896994 | 0.85 | SCN8A (0.67) | SCN1ASCN4ASCN5ASCN9ASCN2A | |
| SCHEMBL1768250 | 0.84 | SCN8A (0.70) | SCN1ASCN4ASCN5ASCN9ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283295-A1 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2012-11-08 | — | — | US | disclosed |
| US-20120283295-A1 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2012-11-08 | — | — | US | disclosed |
| US-20120283295-A1 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2012-11-08 | — | — | US | disclosed |
| EP-2483270-A1 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS | University College London (GB) | 2012-08-08 | — | — | EP | disclosed |
| WO-2011061469-A1 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS | UNIVERSITY COLLEGE LONDON (GB) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283295-A1 | INDAZOLE DERIVATIVES AND THEIR USE FOR BLOCKADING VOLTAGE DEPENDENT SODIUM CHANNELS | SCN3A, CACNB3, CACNA1B | SCN1A 11/4885SCN4A 59/4885SCN5A 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.